Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- S&P 500 ends higher as investors await tech earnings
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Fate Therapeutics (FATE) Misses Q3 EPS by 2c
November 5, 2019 5:11 PM ESTFate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.40), $0.02 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $2.43 million versus the consensus estimate of $1.79 million.
First Patients Treated with FT516, an Off-the-Shelf NK Cell Cancer Immunotherapy for AML and for B-cell Lymphoma in Combination with RituximabReceived FDA Clearance of IND Application for FT596, an Off-the-Shelf, Multi-Antigen... More